Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
27.19
-1.44 (-5.03%)
Jul 31, 2026, 12:06 PM EDT - Market open
Alto Neuroscience Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
68
Market Cap
1.06B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 210.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MeiraGTx Holdings | 79.76M |
| Lexicon Pharmaceuticals | 69.64M |
| Inventiva | 7.94M |
| EyePoint | 7.61M |
| Avalo Therapeutics | 59.00K |
ANRO News
- 18 days ago - Alto Neuroscience prices 3.78M shares at $26.48 in registered direct offering - TheFly
- 18 days ago - Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock - Business Wire
- 6 weeks ago - Alto Neuroscience Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference - Transcripts
- 6 weeks ago - Alto Neuroscience highlights publication in Nature Medicine on Prime-Praxol - TheFly
- 6 weeks ago - Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia - Business Wire
- 6 weeks ago - Alto Neuroscience Slides: Corporate presentation - Filings
- 2 months ago - Alto Neuroscience Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Alto Neuroscience appoints Miller to Board of Directors - TheFly